VJHemOnc is committed to improving our service to you

IMW 2019 | Proof-of-concept approach to overcome proteasome inhibitor resistance in myeloma

VJHemOnc is committed to improving our service to you

Dharminder Chauhan

Dharminder Chauhan, JD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, describes a novel proof-of-concept approach to inhibit the ubiquitin proteasome pathway at the level of ubiquitin receptors and deubiquitylating enzymes, upstream of the 20S-proteasome, with a goal to block tumor growth and overcome proteasome inhibitor resistance in multiple myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter